Skip to main content

Table 6 Laboratory parameters at baseline and post-[177Lu]Lu-DOTA-ZOL treatment

From: [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results

Parameters Patients receiving single cycle Patients receiving 2 cycles
Baseline (median, IQR) Post-treatment (median, IQR) P value Baseline (median, IQR) Post-treatment (median, IQR) P value
Haemoglobin (g/dL) 10.2 (9.6–10.6) 10 (8.9–11) 0.129 14.7 (10–12.4) 13 (9.2–11) < 0.0001
Platelets (lakhs/µL) 172 (140.2–198) 143 (129.2–198.5) 0.039 223 (164–284.25) 217 (170–275.5) 0.421
Leukocytes 109/L 6760 (4210–11,800) 5400 (3700–10,800 0.291 6700 (4280–12,000) 5400 (3800–10,900) 0.298
Creatinine (mg/dL) 0.8 (0.63–0.96) 0.79 (0.6–0.94) 0.259 0.7 (0.7–0.9) 0.8 (0.7–0.8) 0.174
ALP (IU/L) 282 (190–480) 189 (140–280) 0.0001 278 (186–390) 230 (142–340) 0.003
  1. ALP alkaline phosphatase, IQR interquartile range